Key Events This Week
28 Sep: Stock opens at Rs.99.20, down 1.94%
29 Sep: Modest recovery with Rs.99.65 close (+0.45%)
30 Sep: Strong rally to Rs.102.47 (+2.83%)
1 Oct: New 52-week high and upper circuit hit at Rs.107.85
28 September: Weak Start Amid Broader Market Decline
Aarey Drugs & Pharmaceuticals Ltd began the week on a subdued note, closing at Rs.99.20, down 1.94% from the previous Friday’s close of Rs.101.16. This decline was in line with the broader market, as the Sensex fell 1.60% to 34,788.97. The stock’s volume was moderate at 4,009 shares, reflecting cautious investor sentiment amid a negative market environment.
29 September: Slight Recovery Despite Market Pressure
The stock edged up by 0.45% to close at Rs.99.65, showing tentative signs of recovery. However, the Sensex continued its downward trend, slipping 0.48% to 34,621.52. Trading volume decreased to 1,551 shares, indicating limited participation. The stock’s modest gain contrasted with the broader market’s weakness, hinting at underlying resilience.
30 September: Strong Rally Lifts Stock Above Rs.100
Aarey Drugs & Pharmaceuticals Ltd gained significant momentum on 30 September, surging 2.83% to close at Rs.102.47. This rally was accompanied by a substantial increase in volume to 8,323 shares, signalling renewed investor interest. Despite the Sensex’s marginal decline of 0.17% to 34,564.37, the stock’s outperformance was notable, breaking above the psychologically important Rs.100 level and setting the stage for further gains.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
1 October: New 52-Week High and Upper Circuit Hit
The highlight of the week came on 1 October when Aarey Drugs & Pharmaceuticals Ltd surged to an intraday high of Rs.107.85, marking a new 52-week and all-time high. The stock closed at this upper circuit price, up 4.99% for the day, significantly outperforming the Pharmaceuticals & Biotechnology sector which declined 0.59%, and the Sensex which fell 0.99% to 34,221.41.
The stock opened with a gap-up of 4.89% and traded in a narrow range of just Rs.0.06 near the close, indicating a regulatory freeze triggered by the upper circuit hit. Total traded volume was 1.56 lakh shares with a turnover of Rs.1.66 crore. Notably, delivery volumes surged to 3.12 lakh shares on 30 September, a 195.55% increase over the five-day average, signalling strong genuine buying interest rather than speculative trading.
Technically, the stock is trading above all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), confirming a robust upward trend. The sustained momentum over three consecutive sessions has resulted in cumulative gains of 8.31%, underscoring strong investor confidence despite the company’s micro-cap status and a mojo grade of Sell.
However, the mojo grade downgrade from Hold to Sell on 29 May 2026 reflects caution on fundamentals, suggesting investors should balance technical strength with underlying risks. The upper circuit hit also implies limited supply at these elevated levels, which may lead to consolidation or minor correction in the near term.
Considering Aarey Drugs & Pharmaceuticals Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Weekly Price Performance: Stock vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-28 | Rs.99.20 | -1.94% | 34,788.97 | -1.60% |
| 2026-09-29 | Rs.99.65 | +0.45% | 34,621.52 | -0.48% |
| 2026-09-30 | Rs.102.47 | +2.83% | 34,564.37 | -0.17% |
| 2026-10-01 | Rs.103.05 | +0.57% | 34,221.41 | -0.99% |
Key Takeaways
Positive Signals: The stock’s ability to hit a new 52-week high and upper circuit in a week when the Sensex declined by 3.20% highlights strong relative strength and investor demand. The surge in delivery volumes indicates genuine accumulation rather than speculative trading. Technical indicators confirm a robust upward trend with the stock trading above all major moving averages.
Cautionary Notes: Despite the technical strength, the mojo grade remains at Sell with a score of 43.0, reflecting fundamental concerns. The micro-cap status implies higher volatility and lower liquidity, which can lead to sharp price swings. The upper circuit hit may lead to short-term consolidation or correction as the market digests recent gains.
Conclusion
Aarey Drugs & Pharmaceuticals Ltd demonstrated notable resilience and strength during the week ending 2 October 2026, gaining 1.87% while the broader Sensex declined sharply. The stock’s new 52-week high and upper circuit hit on 1 October underscore strong buying interest and positive technical momentum. However, the fundamental rating downgrade and micro-cap classification warrant caution. Investors should monitor upcoming trading sessions closely to assess whether the current momentum sustains or if a consolidation phase emerges. Overall, the stock’s performance this week stands out as a bright spot amid a challenging market backdrop.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
